Table 3.
Protease | Developer | Technology description | Disease indication | Development stage |
---|---|---|---|---|
Liprotamase, protease from the fungus Aspergillus melleus |
Eli Lilly | A component of Trizytek™ (digestive enzymes: lipase, protease and amylase mixture) |
Cystic fibrosis with exocrine pancreatic insufficiency |
Phase III/NDA (New Drug Application) |
Microplasmin | ThromboGenics NV | Recombinant microplasmin injected into the vitreous humour of the eye |
Vitreomacular adhesion | Phase III |
Glutamine-specific cysteine protease (EP-B2) and a proline-specific prolylendopeptidase (PEP), ALV003 |
Alvine Phamraceuticals | Recombinant proteases to digest gluten |
Coeliac disease | Phase II |
Microplasmin | ThromboGenics NV | Recombinant microplasmin | Acute peripheral arterial occlusion, deep vein thrombosis |
Phase II |
Plasmin | Talecris Biotherapeutics | Plasma-derived plasmin | Peripheral arterial occlusion | Phase I |
Recombinant plasmin | Talecris Biotherapeutics | Recombinant plasmin | Peripheral arterial occlusion | Preclinical |
Recombinant plasmin (BLX-155) | Biolex | Recombinant plasmin | Acute peripheral arterial disease, deep vein thrombosis and haemodialysis |
Preclinical |
Recombinant human lysosomal protease, HTI-501 |
Halozyme | Recombinant FVIIa variant, developed with gene shuffling technology |
Medical and cosmetic dermatological applications |
Preclinical |
Kallikrein | Wanxing Pharmaceutical | Recombinant human kallikrein-1 | Thrombosis, peripheral vascular disease, cerebrovascular ischaemia |
Preclinical |
Calpain 3 | Généthon | Gene therapy; adenoviral vectors containing caplain 3 |
Replacement therapy, calpainopathy (a limbgirdle muscular dystophy) |
Discovery |
Penzyme | Zymetech | Proteases that digest outer layers of skin |
Psoriasis, eczema and dermatitis, cosmetic dermatological use |
Marketed for topical use, not FDA-approved |